Overview

Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma

Status:
Recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase Ⅲ randomized, controlled, multi-center, trial comparing cisplatin plus docetaxel to cetuximab, cisplatin, and docetaxel induction chemotherapy followed by concurrent chemoradiation in previously untreated patients metastatic nasopharyngeal carcinoma (mNPC) to determine whether the addition of cetuximab to induction chemotherapy and chemoradiation could improve therapeutic efficacy in mNPC, and investigate predictive and prognostic factors for mNPC.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborator:
Chinese Southwest Oncology Group
Treatments:
Capecitabine
Cetuximab
Cisplatin
Docetaxel